Quantinno Capital Management LP Purchases 9,714 Shares of Ralliant Corporation $RAL

Quantinno Capital Management LP raised its position in shares of Ralliant Corporation (NYSE:RAL) by 15.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,021 shares of the company’s stock after acquiring an additional 9,714 shares during the period. Quantinno Capital Management LP’s holdings in Ralliant were worth $3,079,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Danske Bank A S bought a new stake in Ralliant in the fourth quarter worth $25,000. Allworth Financial LP lifted its position in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. V Square Quantitative Management LLC bought a new position in Ralliant during the fourth quarter valued at $26,000. Palisade Asset Management LLC purchased a new position in shares of Ralliant in the 3rd quarter worth $26,000. Finally, Rothschild Investment LLC raised its position in shares of Ralliant by 98.1% during the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after buying an additional 303 shares in the last quarter.

Ralliant Price Performance

RAL stock opened at $67.52 on Friday. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $75.41. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average price of $67.63 and a 200 day moving average price of $54.81. The stock has a market cap of $7.47 billion, a PE ratio of -6.22, a P/E/G ratio of 2.51 and a beta of 1.60.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.63 by $0.05. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. The company had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities research analysts anticipate that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.84%.

Analyst Ratings Changes

RAL has been the subject of several recent research reports. Wall Street Zen upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. Truist Financial restated a “buy” rating and set a $82.00 price objective (up from $68.00) on shares of Ralliant in a research report on Friday, July 31st. Zacks Research raised Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Oppenheimer lifted their target price on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Finally, Morgan Stanley boosted their target price on Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.